Literature DB >> 7606716

Complex structure and regulation of the P16 (MTS1) locus.

S Stone1, P Jiang, P Dayananth, S V Tavtigian, H Katcher, D Parry, G Peters, A Kamb.   

Abstract

The p16 gene (P16, MTS1, CDKN2) encodes a negative regulator of the cell cycle. Molecular genetic techniques have been used to explore the role of p16 in normal development and cancer. Two transcripts derived from the p16 gene with distinct protein coding potentials are described. The previously undescribed transcript form has the same exons 2 and 3 as the p16-encoding mRNA but contains a different exon 1. The human p16 transcripts are detected in various tissues, and the ratio of the transcripts is regulated in both a tissue-specific and cell cycle-specific manner. The P16-derived mRNAs are probably generated from separate promoters, and transcription from one of the promoters appears to be regulated, at least in part, by the retinoblastoma gene product.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7606716

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  66 in total

1.  Selective association of the methyl-CpG binding protein MBD2 with the silent p14/p16 locus in human neoplasia.

Authors:  F Magdinier; A P Wolffe
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-17       Impact factor: 11.205

2.  Promoter DNA Methylation and mRNA Expression Level of p16 Gene in Oral Squamous Cell Carcinoma: Correlation with Clinicopathological Characteristics.

Authors:  Abdolamir Allameh; Abdolkarim Moazeni-Roodi; Iraj Harirchi; Mehrdad Ravanshad; Maziar Motiee-Langroudi; Ata Garajei; Azin Hamidavi; Seyed Alireza Mesbah-Namin
Journal:  Pathol Oncol Res       Date:  2018-12-03       Impact factor: 3.201

3.  Inhibition of T-cell acute lymphoblastic leukemia proliferation in vivo by re-expression of the p16INK4a tumor suppressor gene.

Authors:  K Schoppmeyer; P S Norris; M Haas
Journal:  Neoplasia       Date:  1999-06       Impact factor: 5.715

4.  Study on the spatial architecture of p53, MDM2, and p14ARF containing complexes.

Authors:  Andrej Savchenko; Mariya Yurchenko; Boris Snopok; Elena Kashuba
Journal:  Mol Biotechnol       Date:  2008-11-07       Impact factor: 2.695

5.  Sequence variation and chromosomal mapping of the murine Cdkn2a tumor suppressor gene.

Authors:  C R Herzog; M You
Journal:  Mamm Genome       Date:  1997-01       Impact factor: 2.957

6.  Cancer-associated mutations at the INK4a locus cancel cell cycle arrest by p16INK4a but not by the alternative reading frame protein p19ARF.

Authors:  D E Quelle; M Cheng; R A Ashmun; C J Sherr
Journal:  Proc Natl Acad Sci U S A       Date:  1997-01-21       Impact factor: 11.205

Review 7.  Determinants of nutrient limitation in cancer.

Authors:  Mark R Sullivan; Matthew G Vander Heiden
Journal:  Crit Rev Biochem Mol Biol       Date:  2019-06-04       Impact factor: 8.250

8.  The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.

Authors:  F J Stott; S Bates; M C James; B B McConnell; M Starborg; S Brookes; I Palmero; K Ryan; E Hara; K H Vousden; G Peters
Journal:  EMBO J       Date:  1998-09-01       Impact factor: 11.598

9.  p16INK4a expression and absence of activated B-RAF are independent predictors of chemosensitivity in melanoma tumors.

Authors:  Stuart J Gallagher; John F Thompson; James Indsto; Lyndee L Scurr; Margaret Lett; Bo-Fu Gao; Ruth Dunleavey; Graham J Mann; Richard F Kefford; Helen Rizos
Journal:  Neoplasia       Date:  2008-11       Impact factor: 5.715

Review 10.  Main roads to melanoma.

Authors:  Giuseppe Palmieri; Mariaelena Capone; Maria Libera Ascierto; Giusy Gentilcore; David F Stroncek; Milena Casula; Maria Cristina Sini; Marco Palla; Nicola Mozzillo; Paolo A Ascierto
Journal:  J Transl Med       Date:  2009-10-14       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.